Author

Daniel Vitt

EFFICACY AND SAFETY OF VIDOFLUDIMUS CALCIUM (IMU-838) IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC): RESULTS FROM THE PROSPECTIVE PLACEBO-CONTROLLED PHASE 2 CALDOSE-1 TRIAL
EFFICACY AND SAFETY OF VIDOFLUDIMUS CALCIUM (IMU-838) IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC): RESULTS FROM THE PROSPECTIVE PLACEBO-CONTROLLED PHASE 2 CALDOSE-1 TRIAL

Daniel Vitt  et al.

FIRST IN HUMAN TRIAL OF IMU-856, AN ORALLY AVAILABLE EPIGENETIC MODULATOR OF BARRIER REGENERATION FOR THE TREATMENT OF CELIAC DISEASE
FIRST IN HUMAN TRIAL OF IMU-856, AN ORALLY AVAILABLE EPIGENETIC MODULATOR OF BARRIER REGENERATION FOR THE TREATMENT OF CELIAC DISEASE

Daniel Vitt  et al.

Item 1 - 2 / 2
1